Regarding IL-6 our data suggest that independent of the driver mutation of the three lung cancer cell lines (NCI-H226, NCI-H2122, and NCI-H1650), treatment with XMD 8-92 significantly reduces its secretion (Fig. 5a). The gene discussed is IL6; the disease is lung carcinoma.